Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

81.45USD
9:06pm IST
Change (% chg)

$1.20 (+1.50%)
Prev Close
$80.25
Open
$80.72
Day's High
$81.45
Day's Low
$80.21
Volume
469,506
Avg. Vol
2,666,512
52-wk High
$86.26
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

Analysis: $11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion (8.12 billion pounds) burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

15 Dec 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

10 Dec 2017

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

10 Dec 2017

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

10 Dec 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

10 Dec 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Dec 10 More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

10 Dec 2017

Gilead's new drug keeps 56 pct of lymphoma trial patients alive

Dec 10 More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

10 Dec 2017

Earnings vs. Estimates